QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Related Article All Versions of this Article: mol.106.024968v1 mol.106.024968v2 69/6/1773    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Related articles in MolPharm Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wilhide, M. E. Articles by Jones, W. K. Search for Related Content PubMed PubMed Citation Articles by Wilhide, M. E. Articles by Jones, W. K.

Perspective

Potential Therapeutic Gene for the Treatment of Ischemic Disease: Ad2/Hypoxia-Inducible Factor-1 (HIF-1)/VP16 Enhances B-Type Natriuretic Peptide Gene Expression via a HIF-1-Responsive Element

Department of Pharmacology and Cell Biophysics, University of Cincinnati, Cincinnati, Ohio

In this issue of Molecular Pharmacology, Luo et al. (p. 1953) present a study employing a HIF-1/VP16 chimera to investigate the mechanism by which this constitutively active transcription factor activates expression of brain natriuretic peptide (BNP). The results define a functional hypoxia responsive element (HRE) in the promoter of the human BNP gene and demonstrate that this HRE is necessary for HIF-1/VP16-induced gene expression in human cardiomyocytes grown under normoxic conditions. Luo et al. also show that a consensus E-box DNA binding sequence is necessary for appropriate BNP regulation. Because HIF-1 is known to elicit protective and beneficial gene expression programs in many scenarios and because BNP is known to be cardioprotective, this study provides support for the therapeutic use of the chimeric HIF-1/VP16 protein in coronary heart disease. However, because HIF-1 is a key regulatory molecule that acts upon a large number of downstream gene networks, there remains a need for further investigation. Particularly useful would be comprehensive gene expression profiling coupled with functional analysis of HIF-1/VP16-regulated genes. The results of such studies will elucidate the mechanism of beneficial effects and address concerns regarding potential adverse effects of activating specific HIF-1/VP16-dependent gene programs.

Address correspondence to: W. Keith Jones, Department of Pharmacology and Cell Biophysics, 231 Albert Sabin Way ML0575, University of Cincinnati, Cincinnati, OH 45267-0575. E-mail: joneswk{at}uc.edu

Related articles in MolPharm:

A Constitutively Active Hypoxia-Inducible Factor-1/VP16 Hybrid Factor Activates Expression of the Human B-Type Natriuretic Peptide Gene

Yuxia Luo, Canwen Jiang, Adam J. Belanger, Geoffrey Y. Akita, Samuel C. Wadsworth, Richard J. Gregory, and Karen A. Vincent
MolPharm 2006 69: 1953-1962. [Abstract] [Full Text]